A pharmaceutical company brought on Christopher Gerardi to estimate economic damages arising from alleged infringement and at-risk launch of a patented oral antihyperglycemic drug used in the management of type 2 diabetes. The alleged economic damages were estimated according to appropriateness and, if so, quantum of lost profits, price erosion, and reasonable royalty elements.
CRA consultants named top IP strategists in IAM Strategy 300 2021
Robert Goldman, Daniel McGavock, Dr. Richard Razgaitis, and Larry Rosenberg were recognized in the latest edition of IAM Strategy 300 – The World’s Leading IP...